Skip to main content
x
Dartmouth-Hitchcock logo
Summer Flowers In This Section
 
Controlled Trial of 3,4 Diaminopyridine in Lambert-Eaton Myasthenic Syndrome (LEMS)
Principal Investigator (?)
Study Number
D04013
Summary
The main purpose for this study is to provide access to 3,4 DAP, a drug which has demonstrated to be effective in treating weakness associated with Lambert-Eaton Myasthenic Syndrome. LEMS is a rare autoimmune cause of a defect in neuromuscular transmission. The disorder is clinically characterized by fluctuating muscle weakness, hyporeflexia and autonomic dysfunction. 
Phase (?)
Phase III
Contact

Pauline LeBlanc

Available at the following location(s)

Lebanon

View more details from ClinicalTrials.gov.

0